Startups
One of the biggest areas of research when it comes to cancer is prediction, because the sooner cancer is detected, the higher the chance that the patient will survive. In most cases, cancer is diagnosed after it has already entered into the advanced stages, which severely decreases the effectiveness of current cancer treatments.
Three Boston-area developers, King Street Properties, Mugar Enterprises and the DiStefano family, have proposed a possible new life sciences campus in the area to compete with Kendall Square. It is a 607,900-square-foot campus on a 4.3-acre site in Allston, an officially recognized neighborhood of Boston.
Based in San Diego, Mirum entered into the agreement with Shire for the exclusive global rights to develop and market maralixibat, a Phase II oral inhibitor of the apical sodium-dependent bile acid transporter (ASBT).
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
OptiBiotix Health has named Adam Reynolds as Non-Executive Chairman of its new specialist probiotic subsidiary ProBiotix Health Limited. With 14 commercial deals in just under 18 months and a strong deal pipeline in place ProBiotix is well placed to become a stand-alone company.
VTU Technology GmbH announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
Researchers with Stanford University Jonathan Rothbard and Lawrence Steinman, formed Katexco Pharmaceuticals. Katexco will focus on developing oral therapies for inflammatory diseases based on cannabis and nicotine receptors.
LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.
Pharma giant Pfizer and Bain Capital teamed up to launch Cerevel Therapeutics, a new biopharmaceutical company based in Boston that will focus on developing therapies to treat central nervous system disorders.
Qpex Biopharma, a company spun-out of The Medicines Company focused on the development of anti-infective assets, launched this morning supported by a $33 million Series A financing round and a BARDA contract worth up to $132 million.
PRESS RELEASES